


Rezosicone
CAS 1414777-24-4
MF C29H40O2 MW420.63
3β-(benzyloxy)-17-methylpregn-5-en-20-one
cannabinoid CB1 receptor signalling inhibitor, S79V5L677D
1-[(3S,8R,9S,10R,13S,14S,17S)-10,13,17-trimethyl-3-phenylmethoxy-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl]ethanone
1-((3S,8R,9S,10R,13S,14S,17S)-3-(benzyloxy)-10,13,17-trimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethan-1-one
Pregn-5-en-20-one, 17-methyl-3-(phenylmethoxy)-, (3β)-
3β-(benzyloxy)-17-methylpregn-5-en-20-one
Rezosicone is a potent and selective cannabinoid CB1 receptor signaling inhibitor (or antagonist) primarily used in biochemical and pharmacology research
Biological Mechanism
Rezosicone selectively binds to and inhibits the CB1 receptor. CB1 receptors are heavily concentrated in the central nervous system and play a key role in regulating appetite, pain sensation, mood, and memory. Compounds in this class are frequently studied in research related to metabolic disorders, obesity, and addiction
Pat
https://patentscope.wipo.int/search/en/detail.jsf?docId=EP339768848&_cid=P12-MT571S-81533-1




Synthesis of the 3β-(benzyloxy)-17α-methyl-pregn-5-en-20-one

[0104] MgO (100 mg; 2.42 mmol; 2 eq.) and 2-benzyloxy-1-methylpyridinium Inflate (850 mg; 2.42 mmol; 2.0 eq.) were added to a solution of 17a-methyl-pregnenolone (400 mg; 1.21 mmol; 1 eq.) in trifluorotoluene (10 ml). The reaction medium was stirred for one night at 85°C, then filtered on celite and evaporated under reduced pressure. The residue was purified by chromatography on silica gel (eluent: cyclohexane/AcOEt 95/5) then by crystallisation in acetone to give the 3β-(benzyloxy)-17α-methyl-pregn-5-en-20-one (0.28 g; 36%) as a white solid.
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma



AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

References
- 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disordersPublication Number:US-2022017562-A1Priority Date:2018-12-18
- 3beta-(BENZYLOXY)-17alpha-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERSPublication Number:HR-P20241376-T1Priority Date:2018-12-18
- 3-beta-(benzyloxy)-17-alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disordersPublication Number:HU-E068626-T2Priority Date:2018-12-18
- 3-(BENZYLIOX)-17-METHYLPREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERSPublication Number:FI-3897655-T3Priority Date:2018-12-18Grant Date:2024-09-17
- 3BETA-(BENZYLOXY)-17ALPHA-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERSPublication Number:MA-54518-B1Priority Date:2018-12-18
- 3BETA-(BENZYLOXY)-17ALPHA-METHYLPREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERSPublication Number:SM-T202400425-T1Priority Date:2018-12-18
- 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disordersPublication Number:ZA-202103284-BPriority Date:2018-12-18
- 3Beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disordersPublication Number:ES-2987823-T3Priority Date:2018-12-18Grant Date:2024-11-18
- 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disordersPublication Number:DK-3897655-T3Priority Date:2018-12-18Grant Date:2024-09-23
- 3beta-(BENZYLOXY)-17alpha-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERSPublication Number:EP-3897655-A1Priority Date:2018-12-18
- 3BETA-(BENZYLOXY)-17ALFA-METHYL-PREGN-5-EN-20-ONE FOR USE IN TREATMENT OF COGNITIVE DISORDERSPublication Number:PL-3897655-T3Priority Date:2018-12-18
- 3beta-(Benzyloxy)-17α-methyl-pregn-5-en-20-one for use in the treatment of cognitive disordersPublication Number:MD-3897655-T2Priority Date:2018-12-18
- 3BETA-(BENZYLOXY)-17ALPHA-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERSPublication Number:PT-3897655-TPriority Date:2018-12-18
- 3BETA-(BENZYLOXY)-17ALPHA-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERSPublication Number:RS-66013-B1Priority Date:2018-12-18
- 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disordersPublication Number:EP-3897655-B1Priority Date:2018-12-18Grant Date:2024-07-17
- 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERSPublication Number:WO-2020127468-A1Priority Date:2018-12-18
- 3β-(Benzyloxy)-17α-methyl-pregnant-5-en-20-one for the treatment of cognitive impairmentPublication Number:CN-113260366-BPriority Date:2018-12-18Grant Date:2024-03-08
- 3BETA-(BENZYLOXY)-17ALPHA-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERSPublication Number:LT-3897655-TPriority Date:2018-12-18
- 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disordersPublication Number:EP-3669876-A1Priority Date:2018-12-18
///////rezosicone, anax labs, cannabinoid CB1 receptor signalling inhibitor, S79V5L677D
#rezosicone, #anax labs, #cannabinoid CB1 receptor signalling inhibitor, #S79V5L677D
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
